The clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) founded in 2018 shared updates on the two clinical trials as well as its plan to streamline its workforce with significant layoffs. 

Trials For Treatment-Resistant Depression

atai is currently involved in two clinical trials which aim to develop new options for Treatment-Resistant Depression (TRD.)

The most advanced to date is COMPASS’ synthetic psilocybin program. Proprietary COMP360 in conjunction with psychological support has provided positive results in depressive symptom severity on its multisite Phase 2b trial and is now advancing towards two concurrent Phase 3 trials.

Recent news includes an acceleration of Pivotal Trial 1 (COMP 005) following already achieved results, with top-line data is expected in the …

Full story available on